EPA- and DHA-derived resolvins’ actions in inflammatory bowel disease

European Journal of Pharmacology

Volumn 785, Issue , 2016, Pages 156-164

  Schwanke, Raquel Cristina ^a   Marcon, Rodrigo ^a   Bento, Allisson Freire ^a   Calixto, João B ^a,b  

^a Center of Innovation and Preclinical Studies CIEnP   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Experimental models; Inflammatory bowel diseases; Omega 3 fatty acid; Pro resolution; Resolvins

Indexed keywords

AUTACOID; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; RESOLVIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; DISEASE CONTROL; DISEASE MODEL; FATTY ACID METABOLISM; HUMAN; INFLAMMATORY BOWEL DISEASE; NOCICEPTIVE PAIN; NONHUMAN; PRIORITY JOURNAL; ANIMAL; COMPLICATION; METABOLISM; NOCICEPTION; PATHOPHYSIOLOGY; VISCERAL PAIN;

ANIMALS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; HUMANS; INFLAMMATORY BOWEL DISEASES; NOCICEPTION; VISCERAL PAIN;

EID: 84940731897     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.08.050     Document Type: Article

References (129)

1. Abraham, C., Cho, J.H., Inflammatory bowel disease. N. Engl. J. Med., 361, 2009, 2066.
2. Al-Chaer, E.D., Kawasaki, M., Pasricha, P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology, 119, 2000, 1276.
3. Arita, M., Bianchini, F., Aliberti, J., Sher, A., Chiang, N., Hong, S., Yang, R., Petasis, N.A., Serhan, C.N., Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med., 201, 2005, 713.
4. Arita, M., Yoshida, M., Hong, S., Tjonahen, E., Glickman, J.N., Petasis, N.A., Blumberg, R.S., Serhan, C.N., Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. USA, 102, 2005, 7671.
5. Bang, S., Yoo, S., Yang, T.J., Cho, H., Kim, Y.G., Hwang, S.W., Resolvin D1 attenuates activation of sensory transient receptor potential channels leading to multiple anti-nociception. Br. J. Pharmacol., 161, 2010, 707.
6. Bannenberg, G., Serhan, C.N., Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim. Biophys. Acta, 1801, 2010, 1260.
7. Bannenberg, G.L., Chiang, N., Ariel, A., Arita, M., Tjonahen, E., Gotlinger, K.H., Hong, S., Serhan, C.N., Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol., 174, 2005, 4345.
8. Bar-Meir, S., Chowers, Y., Lavy, A., Abramovitch, D., Sternberg, A., Leichtmann, G., Reshef, R., Odes, S., Moshkovitz, M., Bruck, R., Eliakim, R., Maoz, E., Mittmann, U., Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology, 115, 1998, 835.
9. Baron, J.H., Inflammatory bowel disease up to 1932. Mt. Sinai J. Med., 67, 2000, 174.
10. Baumgart, D.C., Targan, S.R., Dignass, A.U., Mayer, L., van Assche, G., Hommes, D.W., Hanauer, S.B., Mahadevan, U., Reinisch, W., Plevy, S.E., Salzberg, B.A., Buchman, A.L., Mechkov, G.M., Krastev, Z.A., Lowder, J.N., Frankel, M.B., Sandborn, W.J., Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm. Bowel Dis., 16, 2010, 620.
11. Bento, A.F., Claudino, R.F., Dutra, R.C., Marcon, R., Calixto, J.B., Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J. Immunol., 187, 2011, 1957.
12. Bento, A.F., Leite, D.F., Marcon, R., Claudino, R.F., Dutra, R.C., Cola, M., Martini, A.C., Calixto, J.B., Evaluation of chemical mediators and cellular response during acute and chronic gut inflammatory response induced by dextran sodium sulfate in mice. Biochem. Pharmacol., 84, 2012, 1459.
13. Birrenbach, T., Bocker, U., Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm. Bowel Dis., 10, 2004, 848.
14. Brooke, B.N., What is ulcerative colitis?. Lancet, 1, 1953, 1220.
15. Camilleri, M., Williams, D.E., Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. Pharmacoeconomics, 17, 2000, 331.
16. Campbell, E.L., Louis, N.A., Tomassetti, S.E., Canny, G.O., Arita, M., Serhan, C.N., Colgan, S.P., Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J., 21, 2007, 3162.
17. Campbell, E.L., MacManus, C.F., Kominsky, D.J., Keely, S., Glover, L.E., Bowers, B.E., Scully, M., Bruyninckx, W.J., Colgan, S.P., Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. Proc. Natl. Acad. Sci. USA., 107(32), 2010, 14298.
18. Cervero, F., Sensory innervation of the viscera: peripheral basis of visceral pain. Physiol. Rev., 74, 1994, 95.
19. Chapkin, R.S., Kim, W., Lupton, J.R., McMurray, D.N., Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. Prostaglandins Leukot. Essent. Fat. Acids, 81, 2009, 187.
20. Colina, F., Molero, A., Casis, B., Martinez-Montiel, P., Infliximab-related hepatitis: a case study and literature review. Dig. Dis. Sci., 58, 2013, 3362.
21. Crohn, B.B., Ginzburg, L., Oppenheimer, G.D., Landmark article Oct 15, 1932. Regional ileitis. A pathological and clinical entity. By Burril B. Crohn, Leon Ginzburg, and Gordon D. Oppenheimer. JAMA, 251, 1984, 73.
22. Claudino, R.F., Marcon, R., Bento, A.F., Chichorro, J.G., Rae, G.A., Endothelins implicated in referred mechanical hyperalgesia associated with colitis induced by TNBS in mice. Can. J. Physiol. Pharmacol., 88, 2010, 661.
23. Dalli, J., Zhu, M., Vlasenko, N.A., Deng, B., Haeggstrom, J.Z., Petasis, N.A., Serhan, C.N., The novel 13S,14S-epoxy-maresins is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J., 27, 2013, 2573.
24. Danno, K., Ikai, K., Imamura, S., Anti-inflammatory effects of eicosapentaenoic acid on experimental skin inflammation models. Arch. Dermatol. Res., 285, 1993, 432.
25. Dooremont, D., Decaestecker, J., De Wulf, D., Ghillebert, G., Van Vlierberghe, H., Van Dorpe, J., Baert, F., Azathioprine induced serious portal hypertension: a case series of three IBD patients and review of the literature. Acta Gastroenterol. Belg., 76, 2013, 342.
26. Dyerberg, J., Bang, H.O., Stoffersen, E., Moncada, S., Vane, J.R., Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?. Lancet, 2, 1978, 117.
27. Ekbom, A., Helmick, C.G., Zack, M., Holmberg, L., Adami, H.O., Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology, 103, 1992, 954.
28. Elson, C.O., Cong, Y., McCracken, V.J., Dimmitt, R.A., Lorenz, R.G., Weaver, C.T., Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol. Rev., 206, 2005, 260.
29. Elson, C.O., Sartor, R.B., Tennyson, G.S., Riddell, R.H., Experimental models of inflammatory bowel disease. Gastroenterology, 109, 1995, 1344.
30. Ford, A.C., Kane, S.V., Khan, K.J., Achkar, J.P., Talley, N.J., Marshall, J.K., Moayyedi, P., Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am. J. Gastroenterol., 106, 2011, 617.
31. Fraser, A.G., Orchard, T.R., Jewell, D.P., The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut, 50, 2002, 485.
32. GlaxoSmithKline, 2014. A study to investigate the efficacy and safety of GSK1605786A in the treatment of subjects with moderately-to-severely active Crohn's disease (SHIELD-1). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014- [cited 2015 Apr 21]. Available from: 〈https://clinicaltrials.gov/ct2/show/NCT01277666〉 NLM Identifier: NCT01277666.
33. Gyongyosi, N., Lorincz, K., Karpati, S., Wikonkal, N., Development of lupus erythematosus during infliximab therapy. Orv. Hetil., 154, 2013, 590.
34. Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., Mayer, L.F., Schreiber, S., Colombel, J.F., Rachmilewitz, D., Wolf, D.C., Olson, A., Bao, W., Rutgeerts, P., Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet, 359, 2002, 1541.
35. Hanauer, S.B., Sandborn, W., Management of Crohn's disease in adults. Am. J. Gastroenterol., 96, 2001, 635.
36. Hansson, G.K., Libby, P., The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol., 6, 2006, 508.
37. Hommes, D.W., van de Heisteeg, B.H., van der Spek, M., Bartelsman, J.F., van Deventer, S.J., Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital. Inflamm. Bowel Dis., 8, 2002, 81.
38. Horrobin, D.F., Low prevalences of coronary heart disease (CHD), psoriasis, asthma and rheumatoid arthritis in Eskimos: are they caused by high dietary intake of eicosapentaenoic acid (EPA), a genetic variation of essential fatty acid (EFA) metabolism or a combination of both?. Med. Hypotheses, 22, 1987, 421.
39. Hospital, N.C.S., 2015. Effect of Increlex® on children with Crohn disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015- [cited 2015 Apr 21]. Available from: 〈tps://clinicaltrials.gov/ct2/show/NCT00764699〉 NLM Identifier: NCT00764699.
40. Hudesman, D., Lichtiger, S., Sands, B., Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature. Inflamm. Bowel Dis., 19, 2013, 644.
41. Ishida, T., Yoshida, M., Arita, M., Nishitani, Y., Nishiumi, S., Masuda, A., Mizuno, S., Takagawa, T., Morita, Y., Kutsumi, H., Inokuchi, H., Serhan, C.N., Blumberg, R.S., Azuma, T., Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm. Bowel Dis., 16, 2010, 87.
42. Isobe, Y., Arita, M., Matsueda, S., Iwamoto, R., Fujihara, T., Nakanishi, H., Taguchi, R., Masuda, K., Sasaki, K., Urabe, D., Inoue, M., Arai, H., Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J. Biol. Chem., 287, 2012, 10525.
43. Jarnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlen, P., Granno, C., Vilien, M., Strom, M., Danielsson, A., Verbaan, H., Hellstrom, P.M., Magnuson, A., Curman, B., Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology, 128, 2005, 1805.
44. Klotz, U., Maier, K.E., Pharmacology and pharmacokinetics of 5-aminosalicylic acid. Dig. Dis. Sci., 32, 1987, 46S.
45. Koduri, P.R., Vanajakshi, S., Anuradha, R., Azathioprine-associated pure red cell aplasia in renal transplant recipients: a report of two cases. Ann. Hematol., 93, 2014, 329.
46. Kohli, P., Levy, B.D., Resolvins and protectins: mediating solutions to inflammation. Br. J. Pharmacol., 158, 2009, 960.
47. Kromann, N., Green, A., Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. Acta Med. Scand., 208, 1980, 401.
48. Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K., Muller, W., Interleukin-10-deficient mice develop chronic enterocolitis. Cell, 75, 1993, 263.
49. Kurata, J.H., Kantor-Fish, S., Frankl, H., Godby, P., Vadheim, C.M., Crohn's disease among ethnic groups in a large health maintenance organization. Gastroenterology, 102, 1992, 1940.
50. Kusunoki, M., Moeslein, G., Shoji, Y., Fujita, S., Yanagi, H., Sakanoue, Y., Saito, N., Utsunomiya, J., Steroid complications in patients with ulcerative colitis. Dis. Colon Rectum, 35, 1992, 1003.
51. Lau, C.S., Morley, K.D., Belch, J.J., Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis–a double-blind placebo controlled study. Br. J. Rheumatol., 32, 1993, 982.
52. Lawrence, T., Willoughby, D.A., Gilroy, D.W., Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev. Immunol., 2, 2002, 787.
53. Leaf, A., Historical overview of n-3 fatty acids and coronary heart disease. Am. J. Clin. Nutr., 87, 2008, 1978S.
54. LeBlanc, C.J., Horohov, D.W., Bauer, J.E., Hosgood, G., Mauldin, G.E., Effects of dietary supplementation with fish oil on in vivo production of inflammatory mediators in clinically normal dogs. Am. J. Vet. Res., 69, 2008, 486.
55. Libby, P., Atherosclerosis: the new view. Sci. Am., 286, 2002, 46.
56. Lima-Garcia, J.F., Dutra, R.C., da Silva, K., Motta, E.M., Campos, M.M., Calixto, J.B., The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br. J. Pharmacol., 164, 2011, 278.
57. M'Koma, A.E., Inflammatory bowel disease: an expanding global health problem. Clin. Med. Insights Gastroenterol., 6, 2013, 33.
58. Mahadevan, U., Sandborn, W.J., Diagnosis and management of pouchitis. Gastroenterology, 124, 2003, 1636.
59. Maneiro, J.R., Lopez-Canoa, N., Salgado, E., Gomez-Reino, J.J., Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis. Rheumatology, 53, 2014, 834.
60. Marcon, R., Bento, A.F., Dutra, R.C., Bicca, M.A., Leite, D.F., Calixto, J.B., Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis. J. Immunol., 191, 2013, 4288.
61. Maxion-Bergemann, S., Thielecke, F., Abel, F., Bergemann, R., Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics, 24, 2006, 21.
62. Mayer, E.A., Collins, S.M., Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology, 122, 2002, 2032.
63. McLean, L.P., Cross, R.K., Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev. Gastroenterol. Hepatol., 8, 2014, 223.
64. Merched, A.J., Ko, K., Gotlinger, K.H., Serhan, C.N., Chan, L., Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J., 22, 2008, 3595.
65. Mimura, T., Rizzello, F., Helwig, U., Poggioli, G., Schreiber, S., Talbot, I.C., Nicholls, R.J., Gionchetti, P., Campieri, M., Kamm, M.A., Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol. Ther., 16, 2002, 909.
66. Mocci, G., Marzo, M., Papa, A., Armuzzi, A., Guidi, L., Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J. Crohns Colitis, 7, 2013, 769.
67. Morris, G.P., Beck, P.L., Herridge, M.S., Depew, W.T., Szewczuk, M.R., Wallace, J.L., Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology, 96, 1989, 795.
68. Nauroth, J.M., Liu, Y.C., Van Elswyk, M., Bell, R., Hall, E.B., Chung, G., Arterburn, L.M., Docosahexaenoic acid (DHA) and docosapentaenoic acid (DPAn-6) algal oils reduce inflammatory mediators in human peripheral mononuclear cells in vitro and paw edema in vivo. Lipids, 45, 2010, 375.
69. Ness, T.J., Gebhart, G.F., Visceral pain: a review of experimental studies. Pain, 41, 1990, 167.
70. Nguyen, G.C., Torres, E.A., Regueiro, M., Bromfield, G., Bitton, A., Stempak, J., Dassopoulos, T., Schumm, P., Gregory, F.J., Griffiths, A.M., Hanauer, S.B., Hanson, J., Harris, M.L., Kane, S.V., Orkwis, H.K., Lahaie, R., Oliva-Hemker, M., Pare, P., Wild, G.E., Rioux, J.D., Yang, H., Duerr, R.H., Cho, J.H., Steinhart, A.H., Brant, S.R., Silverberg, M.S., Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am. J. Gastroenterol., 101, 2006, 1012.
71. Ogawa, S., Urabe, D., Yokokura, Y., Arai, H., Arita, M., Inoue, M., Total synthesis and bioactivity of resolvin E2. Org. Lett., 11, 2009, 3602.
72. Ostanin, D.V., Bao, J., Koboziev, I., Gray, L., Robinson-Jackson, S.A., Kosloski-Davidson, M., Price, V.H., Grisham, M.B., T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am. J. Physiol. Gastrointest. Liver Physiol., 296, 2009, G135.
73. Palmen, M.J., Dijkstra, C.D., van der Ende, M.B., Pena, A.S., van Rees, E.P., Anti-CD11b/CD18 antibodies reduce inflammation in acute colitis in rats. Clin. Exp. Immunol., 101, 1995, 351.
74. Present, D.H., Meltzer, S.J., Krumholz, M.P., Wolke, A., Korelitz, B.I., 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann. Intern. Med., 111, 1989, 641.
75. Present, D.H., Rutgeerts, P., Targan, S., Hanauer, S.B., Mayer, L., van Hogezand, R.A., Podolsky, D.K., Sands, B.E., Braakman, T., DeWoody, K.L., Schaible, T.F., van Deventer, S.J., Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med., 340, 1999, 1398.
76. Prianichnikova, M.B., 1987. Prevention of bladder cancer in relation to epidemiological data. Urol Nefrol (Mosk), 58.
77. Quigley, E.M., Bytzer, P., Jones, R., Mearin, F., Irritable bowel syndrome: the burden and unmet needs in Europe. Dig. Liver Dis., 38, 2006, 717.
78. Raederstorff, D., Pantze, M., Bachmann, H., Moser, U., Anti-inflammatory properties of docosahexaenoic and eicosapentaenoic acids in phorbol-ester-induced mouse ear inflammation. Int. Arch. Allergy Immunol., 111, 1996, 284.
79. Reinisch, W., de Villiers, W., Bene, L., Simon, L., Racz, I., Katz, S., Altorjay, I., Feagan, B., Riff, D., Bernstein, C.N., Hommes, D., Rutgeerts, P., Cortot, A., Gaspari, M., Cheng, M., Pearce, T., Sands, B.E., Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm. Bowel Dis., 16, 2010, 233.
80. Rogerio, A.P., Haworth, O., Croze, R., Oh, S.F., Uddin, M., Carlo, T., Pfeffer, M.A., Priluck, R., Serhan, C.N., Levy, B.D., Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses. J. Immunol., 189, 2012, 1983.
81. Rosenfeld, G., Qian, H., Bressler, B., The risks of post-operative complications following pre-operative infliximab therapy for Crohn's disease in patients undergoing abdominal surgery: a systematic review and meta-analysis. J. Crohns Colitis, 7, 2013, 868.
82. Rutgeerts, P., Sandborn, W.J., Feagan, B.G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S.B., Lichtenstein, G.R., de Villiers, W.J., Present, D., Sands, B.E., Colombel, J.F., Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med., 353, 2005, 2462.
83. Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A.C., Horak, I., Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell, 75, 1993, 253.
84. Samuelsson, B., Dahlen, S.E., Lindgren, J.A., Rouzer, C.A., Serhan, C.N., Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science, 237, 1987, 1171.
85. Sandborn, W.J., Yednock, T.A., Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am. J. Gastroenterol., 98, 2003, 2372.
86. Saw, C.L., Huang, Y., Kong, A.N., Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid. Biochem. Pharmacol., 79, 2010, 421.
87. Schroeder, K.W., Tremaine, W.J., Ilstrup, D.M., Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med., 317, 1987, 1625.
88. Schwab, J.M., Chiang, N., Arita, M., Serhan, C.N., Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature, 447, 2007, 869.
89. Seki, H., Tani, Y., Arita, M., Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1. Prostaglandins Other Lipid Mediat., 89, 2009, 126.
90. Serhan, C.N., Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?. Am. J. Pathol., 177, 2010, 1576.
91. Serhan, C.N., Arita, M., Hong, S., Gotlinger, K., Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids, 39, 2004, 1125.
92. Serhan, C.N., Brain, S.D., Buckley, C.D., Gilroy, D.W., Haslett, C., O'Neill, L.A., Perretti, M., Rossi, A.G., Wallace, J.L., Resolution of inflammation: state of the art, definitions and terms. FASEB J., 21, 2007, 325.
93. Serhan, C.N., Chiang, N., Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entree for resoleomics. Rheum. Dis. Clin. North Am., 30, 2004, 69.
94. Serhan, C.N., Chiang, N., Van Dyke, T.E., Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol., 8, 2008, 349.
95. Serhan, C.N., Dalli, J., Colas, R.A., Winkler, J.W., Chiang, N., Protectins and maresins: new pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochim. Biophys. Acta, 1851, 2015, 397.
96. Serhan, C.N., Gotlinger, K., Hong, S., Arita, M., Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat., 73, 2004, 155.
97. Serhan, C.N., Gotlinger, K., Hong, S., Lu, Y., Siegelman, J., Baer, T., Yang, R., Colgan, S.P., Petasis, N.A., Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J. Immunol., 176, 2006, 1848.
98. Serhan, C.N., Hong, S., Gronert, K., Colgan, S.P., Devchand, P.R., Mirick, G., Moussignac, R.L., Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med., 196, 2002, 1025.
99. Serhan, C.N., Petasis, N.A., Resolvins and protectins in inflammation resolution. Chem. Rev., 111, 2011, 5922.
100. Serhan, C.N., Savill, J., Resolution of inflammation: the beginning programs the end. Nat. Immunol., 6, 2005, 1191.
101. Serhan, C.N., Takano, T., Chiang, N., Gronert, K., Clish, C.B., Formation of endogenous “antiinflammatory” lipid mediators by transcellular biosynthesis. Lipoxins and aspirin-triggered lipoxins inhibit neutrophil recruitment and vascular permeability. Am. J. Respir. Crit. Care Med., 161, 2000, S95.
102. Serhan, C.N., Yang, R., Martinod, K., Kasuga, K., Pillai, P.S., Porter, T.F., Oh, S.F., Spite, M., Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med., 206, 2009, 15.
103. Shen, B., Achkar, J.P., Lashner, B.A., Ormsby, A.H., Remzi, F.H., Brzezinski, A., Bevins, C.L., Bambrick, M.L., Seidner, D.L., Fazio, V.W., A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm. Bowel Dis., 7, 2001, 301.
104. Sikandar, S., Dickenson, A.H., Visceral pain: the ins and outs, the ups and downs. Curr. Opin. Support. Palliat. Care, 6, 2012, 17.
105. Simopoulos, A.P., Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr., 21, 2002, 495.
106. Sninsky, C.A., Cort, D.H., Shanahan, F., Powers, B.J., Sessions, J.T., Pruitt, R.E., Jacobs, W.H., Lo, S.K., Targan, S.R., Cerda, J.J., et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann. Intern. Med., 115, 1991, 350.
107. Steinhoff, U., Brinkmann, V., Klemm, U., Aichele, P., Seiler, P., Brandt, U., Bland, P.W., Prinz, I., Zügel, U., Kaufmann, S.H., Autoimmune intestinal pathology induced by hsp60-specific CD8 T cells. Immunity, 349, 1999, 358.
108. Strober, W., Fuss, I., Mannon, P., The fundamental basis of inflammatory bowel disease. J. Clin. Invest., 117, 2007, 514.
109. Swaminath, A., Taunk, R., Lawlor, G., Use of methotrexate in inflammatory bowel disease in 2014: a user's guide. World J. Gastrointest. Pharmacol. Ther., 5, 2014, 113.
110. Takahashi, I., Lijima, H., Kishi, D., Kiyono, H., Oligoclonal Th2-biased betabeta T cells induce murine inflammatory bowel disease. Immunol. Res., 20, 1999, 237.
111. Talar-Williams, C., Sneller, M.C., Complications of corticosteroid therapy. Eur. Arch. Otorhinolaryngol., 251, 1994, 131.
112. Targan, S.R., Hanauer, S.B., van Deventer, S.J., Mayer, L., Present, D.H., Braakman, T., DeWoody, K.L., Schaible, T.F., Rutgeerts, P.J., A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N. Engl. J. Med., 337, 1997, 1029.
113. Therapeutics, I., 2014a. Safety and efficacy study of oral ferric iron to treat iron deficiency anaemia in quiescent Crohn's disease (AEGIS-2). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014- [cited 2015 Apr 21]. Available from: 〈https://clinicaltrials.gov/ct2/show/NCT01352221〉 NLM Identifier: NCT01352221.
114. Therapeutics, O., 2014b. Safety and efficacy of AST-120 in Mild to moderate Crohn's patients with fistulas. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014- [cited 2015 Apr 21]. Available from: 〈https://clinicaltrials.gov/ct2/show/NCT00321412〉 NLM Identifier: NCT00321412.
115. Travis, S.P., Review article: the management of mild to severe acute ulcerative colitis. Aliment Pharmacol. Ther., 20(Suppl. 4), 2004, S88.
116. Triantafillidis, J.K., Merikas, E., Georgopoulos, F., Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des. Dev. Ther., 5, 2011, 185.
117. Tuskey, A., Behm, B.W., Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease. Clin. Exp. Gastroenterol., 7, 2014, 173.
118. Vegter, S., Tolley, K., Wilson Waterworth, T., Jones, H., Jones, S., Jewell, D., Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis. Aliment Pharmacol. Ther., 38, 2013, 284.
119. Vuitton, L., Koch, S., Peyrin-Biroulet, L., Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment. Curr. Drug Targets, 14, 2013, 1385.
120. Wallace, K.L., Zheng, L.B., Kanazawa, Y., Shih, D.Q., Immunopathology of inflammatory bowel disease. World J. Gastroenterol., 20, 2014, 6.
121. Weldon, S.M., Mullen, A.C., Loscher, C.E., Hurley, L.A., Roche, H.M., Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J. Nutr. Biochem., 18, 2007, 250.
122. Wilks, S., Morbid appearances in the intestine of Miss Bankes. Lond. Med. Times Gaz., 2, 1859, 264.
123. Wirtz, S., Neufert, C., Weigmann, B., Neurath, M.F., Chemically induced mouse models of intestinal inflammation. Nat. Protoc., 2, 2007, 541.
124. Wirtz, S., Neurath, M.F., Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease. Int. J. Colorectal Dis., 15, 2000, 144.
125. Wirtz, S., Neurath, M.F., Mouse models of inflammatory bowel disease. Adv. Drug Deliv. Rev., 59, 2007, 1073.
126. Wood, N.J., IBD: Visilizumab not useful for intravenous steroid-refractory ulcerative colitis. Nat. Rev. Gastroenterol. Hepatol., 8, 2011, 3.
127. Xavier, R.J., Podolsky, D.K., Unravelling the pathogenesis of inflammatory bowel disease. Nature, 448, 2007, 427.
128. Yeter, K.C., Afkhami, M., Brynes, R.K., Quismorio, F.P. Jr., Aplastic anemia secondary to azathioprine in systemic lupus erythematosus: report of a case with normal thiopurine S-methyltransferase enzyme activity and review of the literature. Lupus, 22, 2013, 1526.
129. Zhou, Q., Price, D.D., Caudle, R.M., Verne, G.N., Visceral and somatic hypersensitivity in a subset of rats following TNBS-induced colitis. Pain, 134, 2008, 9.